ACIS ResearchAI Civilization Investment Research中文

PUBLIC RESEARCH · WEEKLY

AI Capital Spending Starts to Deliver, but Higher Rates Reprice Everything

Weekly Alpha Research | Issue 002 | 11 September 2026

Oracle is converting orders into revenue. Adobe’s AI growth still needs paid-conversion evidence. Under higher rates, growth quality depends on cash generation and the financing burden.

The one-minute brief

This issue compares two repricing paths. Oracle shows revenue and contract progress, including customer participation in construction funding. Adobe continues to grow, but free-to-paid conversion and management execution remain open questions. Short-term price reactions should be separated from operating evidence; a low valuation alone does not establish investment value.

Browser voice · tap to play
Audio transcript

This issue compares two repricing paths. Oracle shows revenue and contract progress, including customer participation in construction funding. Adobe continues to grow, but free-to-paid conversion and management execution remain open questions. Short-term price reactions should be separated from operating evidence; a low valuation alone does not establish investment value.

Oracle

Better revenue conversion; financing risks remain

Adobe

AI growth improves; paid conversion needs proof

Higher rates

Cash generation and capital efficiency matter

01 | The market setting

The report cutoff is 11 September 2026, 19:08 Beijing time. Market observations in the source use 10 September closes and 11 September premarket data, before the August CPI release. Higher rates and energy costs raise the evidence bar for earnings quality. These are dated observations, not live market readings.

02 | Oracle: customers help fund construction

Fiscal first-quarter revenue was approximately $19.3 billion, up 30%, with remaining performance obligations of $664 billion. Customer prepayments covered approximately $11.36 billion of $28.5 billion in capital expenditure. Free cash flow remained negative at $5.4 billion. Customer funding eases financing pressure but does not eliminate construction costs or establish positive cash generation.

What changes in the Oracle thesis

The prior concern was whether large contracts would become revenue and whether construction could be funded. Revenue growth and improved contract structures strengthen the conversion thesis. Next tests include backlog conversion, customer concentration, power and construction execution, cloud margins and consecutive quarters of cash flow. Higher spending with weaker prepayment support, or customer delays, would weaken the case.

03 | Adobe: operating progress needs paid validation

Third-quarter revenue was approximately $6.76 billion, up about 13%, with adjusted EPS of $6.13. AI-first annual recurring revenue grew over 150%. Adobe has not simply missed AI, but free-user scale is not paid revenue. Competition, conversion efficiency and leadership transition remain important uncertainties.

The central Adobe debate

A low valuation may reflect excessive pessimism or a lasting reduction in growth. Watch free-to-paid conversion, net new recurring revenue, combined AI and legacy subscription growth, and management execution. If AI gains do not offset core slowing, a low multiple could persist rather than trigger a rerating.

04 | Across sectors: results after the event

Samsara’s operating evidence and post-earnings trading response diverged. Medtronic still needs sustained cardiovascular and other growth. Private credit requires monitoring defaults, redemptions and funding costs; creative software needs competitive and earnings evidence; space businesses need delivery and launch execution. Each industry needs its own operating proof.

Insilico: Phase 3 entry is not Phase 3 success

The source records first-patient dosing in the rentosertib Phase 3 study. This is a development milestone, while efficacy, safety and commercial returns remain uncertain. Potential partnership values include contingent milestones and cannot be treated as recognized revenue. Index inclusion is also distinct from clinical validation.

05 | Next validation: from events to cash flow

For Oracle, follow contract conversion and recurring customer funding. For Adobe, paid conversion and total recurring revenue matter. For Insilico, track enrollment, safety and partnership cash receipts. For stablecoin infrastructure, distinguish planned launches from live operations and integration from paid transactions. Macro releases and central-bank decisions may change discount rates and financing conditions.

06 | Weekly conclusion

AI demand still offers growth opportunities, while higher rates amplify the cost of cash burn, leverage and customer concentration. Oracle and Adobe illustrate financing and paid-conversion hurdles. The research question is whether operating progress can generate sustainable cash, rather than whether an earnings print moved the share price.

Key questions

Does Oracle’s improved cash flow remove the risk?

No. Cash flow remains negative; prepayment durability, construction execution and customer concentration still matter.

Does a low Adobe multiple establish a buying opportunity?

No. Long-term growth and conversion of AI users into paid revenue must be tested.

Why not use the 11 September closing price?

The source cutoff precedes the US regular session. This edition preserves that historical information boundary.

Key terms

Remaining performance obligations (RPO)Contracted amounts not yet recognized as revenue; not current revenue or cash.

Annual recurring revenue (ARR)An annualized recurring-revenue measure, distinct from period accounting revenue.

Free cash flowCommonly operating cash flow less capital expenditure; check the company definition.

FreemiumFree access with monetization through paid features or subscriptions.

Sources and related research

Reuters · Oracle · 2026.09.10

Reuters · Adobe · 2026.09.10

Insilico company release

Edited from the supplied complete research report. Information is fixed at 11 September 2026, 19:08 Beijing time. Financial results, future plans and ACIS judgments are distinguished. For research and education, not personalized investment advice.

Previous issue | 001

Rentosertib human-evidence memo